31.Issue 08 august 23 - INDO AMERICAN JOURNAL OF PHARMACEUTICAL SCIENCES

Volume : 10, Issue : 08, August – 2023

Title:

31.A REVIEW ON NITROSAMINE IMPURITY- SOURCES, ANALYTICAL METHODS, CARCINOGENICITY AND PRESENCE IN VARIOUS DRUGS
‬

Authors :

Hrithika J C, Siva jyothi Buggana, Mamatha Tirunagari*

Abstract :

The presence of N-nitrosamines in pharmaceutical products has caused concern among health regulators and pharmaceutical companies. When nitrates or nitrites react with amines, nitrosamines are formed. Nitrosamines and/or their precursors are present in a variety of consumer items. Some sartan pharmaceutical products were discovered to be contaminated with nitrosamine compounds, which are very carcinogenic. Special emphasis was paid to N-nitrosodimethylamine (NDMA) and N-nitrosodiethylamine (NDEA). The most prevalent Nitrosamines detected are NDMA and NDEA, however there are numerous more Nitrosamines as well. Certain nitrosamines may increase the risk of cancer if people are exposed to them at higher-than-safe levels for an extended period of time. People who consummate NDMA-containing drugs at or below the permissible consumption limits on a daily basis for 70 years are unlikely to get cancer. They can be present in medications, cosmetics, water, and food. Many variables contribute to the development of N-nitrosamine. The Food and Drug Administration classifies two Tobacco Specific Nitrosamines (TSNA) as dangerous and potentially harmful components (HPHCs) in tobacco products and tobacco, N-nitrosonornicotine (NNN) and 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK). Many approaches for detecting nitrosamine have been developed since 1954.
Keywords: Nitrosamine; NNK; NDMA; NDE; NNN; TSNA

Cite This Article:

Please cite this article in press Hrithika J C et al, A Review On Nitrosamine Impurity- Sources, Analytical Methods, Carcinogenicity And Presence In Various Drugs, Indo Am. J. P. Sci, 2023; 10 (08).

Number of Downloads : 10

References:

1. https://www.fda.gov/news-events/press-announcements/fda-requests-removal-all-ranitidine-products-zantac-market
2. https://www.fda.gov/drugs/drug-safety-and-availability/fda-updates-and-press-announcements-ndma-zantac-ranitidine
3. https://www.fda.gov/drugs/drug-safety-and-availability/fda-updates-and-press-announcements-ndma-zantac-ranitidine
4. Borths, Christopher J., Tracey Burr, Aude Figuccia, J. Gair Ford, Bing Guan, Michael T. Jones, Didier Klingeleers, Susanne Lochner, Andrew A. Rodriguez, and Christian Wetter. “Nitrosamine Risk Assessments in Oligonucleotides.” Organic Process Research & Development (2022).
5. Burns, Michael J., Andrew Teasdale, Eric Elliott, and Chris G. Barber. “Controlling a cohort: use of mirabilis-based purge calculations to understand nitrosamine-related risk and control strategy options.” Organic Process Research & Development 24, no. 8 (2020): 1531-1535.
6. Raman, N. V. V. S. S., A. V. S. S. Prasad, and K. Ratnakar Reddy. “Strategies for the identification, control and determination of genotoxic impurities in drug substances: A pharmaceutical industry perspective.” Journal of pharmaceutical and biomedical analysis 55, no. 4 (2011): 662-667.
7. Brendler, S. Y., A. Tompa, K. F. Hutter, R. Preussmann, and B. L. Pool-Zobel. “In vivo and in vitro genotoxicity of several N-nitrosamines in extrahepatic tissues of the rat.” Carcinogenesis 13, no. 12 (1992): 2435-2441.
8. Hinuma, Kazuo, Jun Matsuda, Noritoshi Tanida, Shinji Hori, Kazutami Tamura, Tadatsugu Ohno, Masakatsu Kano, and Takashi Shimoyama. “N-nitrosamines in the stomach with special reference to in vitro formation, and kinetics after intragastric or intravenous administration in rats.” Gastroenterologia Japonica 25 (1990): 417-424.
9. Lijinsky, William, Evelyn Conrad, and Rosalie Van de Bogart. “Carcinogenic nitrosamines formed by drug/nitrite interactions.” Nature 239, no. 5368 (1972): 165-167.
10. Schlingemann, Joerg, Michael J. Burns, David J. Ponting, Carolina Martins Avila, Naiffer E. Romero, Mrunal A. Jaywant, Graham F. Smith et al. “The landscape of potential small and drug substance related nitrosamines in pharmaceuticals.” Journal of Pharmaceutical Sciences 112, no. 5 (2023): 1287-1304.
11. https://www.ema.europa.eu/en/documents/report/lessons-learnt-presence-n-nitrosamine-impurities-sartan-medicines_en.pdf
12. Nawrocki, Jacek, and Przemysław Andrzejewski. “Nitrosamines and water.” Journal of Hazardous Materials 189, no. 1-2 (2011): 1-18.
13. Lijinsky, William. “Reaction of drugs with nitrous acid as a source of carcinogenic nitrosamines.” Cancer research 34, no. 1 (1974): 255-258.
14. Shaikh, Tabrez. “Nitrosamine impurities in drug substances and drug products.” (2020).
15. World Health Organization. “International agency for research on cancer.” (2019).
16. Barnes, J. M., and P. N. Magee. “Some toxic properties of dimethylnitrosamine.” British journal of industrial medicine 11, no. 3 (1954): 167.
17. Hecht, Stephen S. “Approaches to cancer prevention based on an understanding of N-nitrosamine carcinogenesis.” Proceedings of the Society for Experimental Biology and Medicine 216, no. 2 (1997): 181-191.
18. Gushgari, Adam J., and Rolf U. Halden. “Critical review of major sources of human exposure to N-nitrosamines.” Chemosphere 210 (2018): 1124-1136.
19. Li, Kate, Karin Ricker, Feng C. Tsai, ChingYi J. Hsieh, Gwendolyn Osborne, Meng Sun, M. Elizabeth Marder, Sarah Elmore, Rose Schmitz, and Martha S. Sandy. “Estimated cancer risks associated with nitrosamine contamination in commonly used medications.” International journal of environmental research and public health 18, no. 18 (2021): 9465.
20. Lim, Duck Soo, Tae Hyun Roh, Min Kook Kim, Yong Chan Kwon, Seul Min Choi, Seung Jun Kwack, Kyu Bong Kim, Sungpil Yoon, Hyung Sik Kim, and Byung-Mu Lee. “Risk assessment of N-nitrosodiethylamine (NDEA) and N-nitrosodiethanolamine (NDELA) in cosmetics.” Journal of Toxicology and Environmental Health, Part A 81, no. 12 (2018): 465-480.
21. Preussmann, Rudolf, Bertold Spiegelhalder, Gerhard Eisenbrand, Gerd Würtele, and Ingeborg Hofmann. “Urinary excretion of N-nitrosodiethanolamine in rats following its epicutaneous and intratracheal administration and its formation in vivo following skin application of diethanolamine.” Cancer Letters 13, no. 3 (1981): 227-231.
22. Mitch, William A., Jonathan O. Sharp, R. Rhodes Trussell, Richard L. Valentine, Lisa Alvarez-Cohen, and David L. Sedlak. “N-nitrosodimethylamine (NDMA) as a drinking water contaminant: a review.” Environmental engineering science 20, no. 5 (2003): 389-404.
23. Beard, Jessica C., and Timothy M. Swager. “An organic chemist’s guide to N-nitrosamines: their structure, reactivity, and role as contaminants.” The Journal of organic chemistry 86, no. 3 (2021): 2037-2057.
24. Park, Jong-eun, Jung-eun Seo, Jee-yeon Lee, and Hoonjeong Kwon. “Distribution of seven N-nitrosamines in food.” Toxicological research 31 (2015): 279-288.
25. Zahra, Naseem, Muhammad Khalid Saeed, and Muhammad Hassan Raza. “Nitrosamines: Incredibly unsafe contaminants in different food commodities.” Chemistry International 9, no. 1 (2023): 27-36.
26. Wichitnithad, Wisut, Siriwan Nantaphol, Kachathong Noppakhunsomboon, and Pornchai Rojsitthisak. “An update on the current status and prospects of nitrosation pathways and possible root causes of nitrosamine formation in various pharmaceuticals.” Saudi Pharmaceutical Journal (2022).
27. Johnson, George E., Krista Dobo, Bhaskar Gollapudi, Jim Harvey, Julia Kenny, Michelle Kenyon, Anthony Lynch et al. “Permitted daily exposure limits for noteworthy N‐nitrosamines.” Environmental and Molecular Mutagenesis 62, no. 5 (2021): 293-305.
28. Parr, Maria Kristina, and Jan F. Joseph. “NDMA impurity in valsartan and other pharmaceutical products: Analytical methods for the determination of N-nitrosamines.” Journal of pharmaceutical and biomedical analysis 164 (2019): 536-549.
29. Lee, Changha, Wonyong Choi, Young Gyu Kim, and Jeyong Yoon. “UV photolytic mechanism of N-nitrosodimethylamine in water: Dual pathways to methylamine versus dimethylamine.” Environmental science & technology 39, no. 7 (2005): 2101-2106.
30. Chen, Z., Yang, L., Zhai, X., Zhao, S., Li, A. and Shen, J.J.W.S.,. N-nitrosamine formation during chlorination/chloramination of bromide-containing water. Water Science and Technology: Water Supply, 10(3), (2010),462-471.
31. Pérez-Ruiz, Tomás, Carmen Martínez-Lozano, Virginia Tomás, and Jesús Martín. “Automated solid-phase extraction and high-performance liquid chromatographic determination of nitrosamines using post-column photolysis and tris (2, 2′-bipyridyl) ruthenium (III) chemiluminescence.” Journal of Chromatography A 1077, no. 1 (2005): 49-56.
32. Kodamatani, Hitoshi, Shigeo Yamazaki, Keiitsu Saito, Abena Amponsaa-Karikari, Naoya Kishikawa, Naotaka Kuroda, Takashi Tomiyasu, and Yu Komatsu. “Highly sensitive method for determination of N-nitrosamines using high-performance liquid chromatography with online UV irradiation and luminol chemiluminescence detection.” Journal of Chromatography A 1216, no. 1 (2009): 92-98.
33. Zhao, Yuan Yuan, Xin Liu, Jessica M. Boyd, Feng Qin, Jianjun Li, and Xing-Fang Li. “Identification of N-nitrosamines in treated drinking water using nanoelectrospray ionization high-field asymmetric waveform ion mobility spectrometry with quadrupole time-of-flight mass spectrometry.” Journal of chromatographic science 47, no. 1 (2009): 92-96.
34. Andrzejewski, Przemysław, Barbara Kasprzyk-Hordern, and Jacek Nawrocki. “The hazard of N-nitrosodimethylamine (NDMA) formation during water disinfection with strong oxidants.” Desalination 176, no. 1-3 (2005): 37-45.
35. Yamamoto, Eiichi, Hitomi Kan-No, Naomi Tomita, Daisuke Ando, Tamaki Miyazaki, and Ken-ichi Izutsu. “Isolation of N-nitrosodimethylamine from drug substances using solid-phase extraction-liquid chromatography–tandem mass spectrometry.” Journal of Pharmaceutical and Biomedical Analysis 210 (2022): 114561.
36. Kosuri, Eswara Raju, Mayank Bhanti, Mrunal A. Jaywant, Mark Han, Xiaochun Wang, and Marcus Obeng. “A GC-MS/MS Method for Trace Level Quantification of Six Nitrosamine Impurities (NDMA, NDEA, NEIPA, NDIPA, NDPA, and NDBA) in Commercially Used Organic Solvents: Dichloromethane, Ethyl Acetate, Toluene, and O-xylene.” Journal of Pharmaceutical Sciences 112, no. 5 (2023): 1225-1230.
37. Chidella, Kartheek Srinivas, Vijaya Bharathi Dasari, and Jayashree Anireddy. “Ultra-sensitive LC-MS/MS method for the trace level quantification of six potential genotoxic nitrosamine impurities in telmisartan.” American Journal of Analytical Chemistry 12, no. 6 (2021): 227-240.
38. Khorolskiy, Mikhail, Galina Ramenskaya, Alexander Vlasov, Oleg Perederyaev, and Nataliya Maslennikova. “Development and validation of four nitrosamine impurities determination method in medicines of valsartan, losartan, and irbesartan with HPLC-MS/MS (APCI).” Iranian Journal of Pharmaceutical Research: IJPR 20, no. 3 (2021): 541.
39. Vogel, Matthias, and Jochen Norwig. “Analysis of genotoxic N-nitrosamines in active pharmaceutical ingredients and market authorized products in low abundance by means of liquid chromatography–tandem mass spectrometry.” Journal of Pharmaceutical and Biomedical Analysis 219 (2022): 114910.
40. Schmidtsdorff, S., Neumann, J., Schmidt, A.H. and Parr, M.K., 2021. Analytical lifecycle management for comprehensive and universal nitrosamine analysis in various pharmaceutical formulations by supercritical fluid chromatography. Journal of Pharmaceutical and Biomedical Analysis, 197, p.113960.
41. Committee for Medicinal Products for Human Use: Assessment Report on Nitrosamine Impurities in Human Medicinal Products (Procedure Number: EMA/369136/202025), EMA, June 25, 2020.https://www.ema.europa.eu/en/documents/referral/nitrosamines-emea-h-a53-1490-assessment-report en.pdf (Accessed 04 January2021).